Khlifi Abdeljalil, Kacem Olfa, Maroueni Maher, Elgoul Leila, Hidar Samir, Fekih Meriem, Boughizane Sassi, Essaidi Habib, Ben Regaya Lassad, Bibi Mohamed, Ajina Mounir, Khairi Hedi
Tunis Med. 2016 Jun;94(6):167-177.
Objective To investigate the difference in the outcome of ICSI-ET cycles among respondents patients, taking into account the molecule inducer of controlled ovarian stimulation: HP-hMG ou rFSH. Patients and Methods A comparative retrospective study over 62 months including a total of 1005 infertile couples, divided into two groups: HP-HMG (n=125) and rFSH (n=880). Results - The average numbers of retrieved oocytes and matures oocytes were significantly higher in rFSH group rFSH (7,94 ± 2,49, HP-HMG vs 9,05 ± 3,40, rFSH, p=0.0001and 3±2,68, HP-HMG vs 6,65±3,05 , rFSH, p=0,02 respectively). There was no statistically significant difference in the endometrial thickness and estradiol level on hCG injection day, the total amount of administrated gonadotropin and the duration of stimulation. In addition, we did not find a significant difference between the two groups regarding the fertilization, the maturation, the cleavage, top quality embryo, implantation, clinical pregnancy, multiple pregnancies, live birth and miscarriage rates. There was no case of severe ovarian hyperstimulation syndrome. Conclusion - Inspite of a higher number of retrieved and mature oocytes obtained with rFSH, the latter showed no superiority over HP-hMG which seem to be equally efficient and safe for ICSI treatment cycles.
考虑控制性卵巢刺激的分子诱导剂（HP-hMG或重组促卵泡生成素[rFSH]），研究接受体外受精-胚胎移植（ICSI-ET）周期的患者结局差异。患者与方法：一项为期62个月的比较性回顾性研究，共纳入1005对不孕夫妇，分为两组：HP-HMG组（n = 125）和rFSH组（n = 880）。结果：rFSH组回收的卵母细胞和成熟卵母细胞的平均数量显著更高（HP-HMG组回收卵母细胞平均数量为7.94±2.49，rFSH组为9.05±3.40，p = 0.0001；HP-HMG组成熟卵母细胞平均数量为3±2.68，rFSH组为6.65±3.05，p = 0.02）。在注射人绒毛膜促性腺激素（hCG）当天，两组的子宫内膜厚度和雌二醇水平、促性腺激素的总给药量以及刺激持续时间均无统计学显著差异。此外，两组在受精、成熟、卵裂、优质胚胎、着床、临床妊娠、多胎妊娠、活产和流产率方面未发现显著差异。未出现严重卵巢过度刺激综合征病例。结论：尽管rFSH回收的卵母细胞和成熟卵母细胞数量较多，但在ICSI治疗周期中，rFSH并不比HP-hMG更具优势，HP-hMG似乎同样有效且安全。
